FiriX Therapeutics develops the FXTi series, a new generation of ferroptosis inhibitors that act as cellular Kevlar: protecting organs and the central nervous system from iron-driven cell death.
An iron-driven chain reaction destroys the cell membrane from within. Once started, it spreads to neighbouring cells that were otherwise healthy. Blocking this cascade protects tissue that would otherwise be lost.
Labile iron builds up inside the cell, beyond its capacity to store it safely.
Free iron drives oxidative chemistry, generating reactive oxygen species.
Radicals attack polyunsaturated membrane lipids in a self-amplifying chain reaction.
The damaged membrane fails, and ferroptotic death propagates to adjacent cells.
Our founders are leaders in ferroptosis biology. From a library of more than 300 in-house molecules, the FXTi series combines two protective actions in a single compound. One chemistry, many organs: a pipeline in a product.
Terminates the lipid peroxidation chain reaction inside the membrane, where the damage happens.
Modulates how iron is distributed between cellular compartments, removing the fuel that drives the cascade.
Relative potency, linear scale: 1× vs ≈1,000×.
Our data package is built on peer-reviewed work from the founding labs, published in Cell, Nature Communications and Cell Death & Differentiation.
Ferroptosis inhibition preserved liver and lung graft function during ex vivo organ perfusion, in large-animal models that closely mirror clinical practice.
Veeckmans et al., Cell, 2026
In preclinical models of central nervous system disease, ferroptosis inhibition halted disease progression after treatment start, supporting a disease-modifying approach.
Program details available under NDA
FXT-001 builds on strong transplantation data, while our pre-seed financing advances the CNS program toward an IND filing. Further indications are disclosed to partners under NDA.
| Candidate | Indication | DiscoveryLead opt.PreclinicalClinical |
|---|---|---|
| FXT-001 | TransplantationOrgan preservation | |
| FXT-004 / 005 | CNSNeuroprotection | |
| FXT-001 / 002 / 003 | Under NDA | |
| FXT-00x | Under NDA |
Development stages are indicative. Undisclosed programs are shared with qualified partners and investors under a confidentiality agreement.
A complementary team with scientific, financial and commercial expertise, supported by a world-class Scientific Advisory Board and leading clinical opinion leaders.
Operating, venture and life-science capital markets experience.
LinkedInRaised to date, the majority from non-dilutive sources. Our pre-seed round is now open.
We welcome conversations with investors, pharma partners and clinical collaborators. Our full pipeline and data package are available under NDA.
